Loading organizations...

Quanterix is a technology company.
Quanterix develops and commercializes ultra-sensitive digital immunoassay platforms, centered around its proprietary Simoa (Single Molecule Array) technology. This innovative solution digitizes biomarker analysis, enabling the detection of proteins and nucleic acids at exceptionally low concentrations. The platform provides researchers with enhanced capabilities for early disease detection, improved prognosis, and more precise treatment insights.
The company was established in 2007 by Dr. David Walt and Dr. Nick Naclerio. Quanterix originated from Dr. Walt's pioneering academic work at Tufts University, specifically his invention of the Simoa technology. Their foundational insight stemmed from the critical need for highly sensitive biomarker detection to transform healthcare, allowing the revelation of subtle biological changes indicative of disease long before traditional diagnostic methods.
The Simoa platform is utilized by researchers across a broad spectrum of therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease. Quanterix’s vision is to advance precision health by providing tools that deepen the understanding of biomarkers in both healthy states and disease progression. Their ultimate aim is to empower earlier disease intervention and facilitate the development of more effective, tailored treatment approaches, ultimately improving human health outcomes.
Quanterix has raised $96.5M across 6 funding rounds.
Quanterix has raised $96.5M in total across 6 funding rounds.
Quanterix has raised $96.5M in total across 6 funding rounds.
Quanterix's investors include Ziad Bakri, ARCH Venture Partners, Bihua Chen, Trinitas Capital, Lux Capital, David R. Walt, Bain Capital Ventures, Hercules Capital, Tufts University, Flagship Ventures, In-Q-Tel.
Quanterix is a life‑sciences technology company that develops and sells ultra‑sensitive protein biomarker detection instruments, assay kits and laboratory services (Simoa® technology) used to detect disease‑relevant biomarkers at much lower concentrations than conventional immunoassays, supporting research and clinical programs across neurology, oncology, cardiology, immunology and infectious disease.[2][4]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech & Life‑Sciences Landscape
Quick Take & Future Outlook
Quick take: Quanterix’s Simoa technology is a leading ultra‑sensitive protein detection platform that has established a strong research and pharma‑services foothold; its future impact depends on continued assay commercialization, regulatory progress for clinical applications, and competitive dynamics in high‑sensitivity diagnostics.[4][5]
Quanterix has raised $96.5M across 6 funding rounds. Most recently, it raised $8.5M Other Equity in August 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 3, 2017 | $8.5M Other Equity | Ziad Bakri | |
| Mar 1, 2016 | $46.0M Series D | ARCH Venture Partners, Bihua Chen, Trinitas Capital | Lux Capital, David R. Walt, Bain Capital Ventures, Hercules Capital, Tufts University |
| Nov 1, 2012 | $19.0M Series C | ARCH Venture Partners, Flagship Ventures, Lux Capital, Bain Capital Ventures, Flagship Ventures, In-Q-Tel | |
| Mar 6, 2012 | $2.0M Other Equity | ||
| Aug 20, 2011 | $6.0M Other Equity | ARCH Venture Partners, Bain Capital Ventures, Flagship Ventures | |
| Aug 1, 2008 | $15.0M Series A | ARCH Venture Partners, Flagship Ventures, Lux Capital |